title: Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
abstract: Controversy exists regarding the optimal use of the 23-valent pneumococcal conjugate vaccine for the protection of high-risk individuals, such as children and adults with immunocompromising conditions and the elderly. The effectiveness and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) are limited in such high-risk populations compared to the healthy, with meta-analyses failing to provide robust evidence on vaccine efficacy against invasive pneumococcal disease (IPD) or pneumonia. Moreover, several studies have demonstrated a PPV23-induced state of immune tolerance or hyporesponsiveness to subsequent vaccination, where the response to revaccination does not reach the levels achieved with primary vaccination. The clinical significance of hyporesponsiveness is not yet clarified, but attenuated humoral and cellular response could lead to reduced levels of protection and increased susceptibility to pneumococcal disease. As disease epidemiology among high-risk groups shows that we are still in need of maximum serotype coverage, the optimal use of PPV23 in the context of combined conjugate/polysaccharide vaccine schedules is an important priority. In this minireview, we discuss PPV23-induced hyporesponsiveness and its implications in designing highly effective vaccination schedules for the optimal protection for high-risk individuals.
authors.affiliation: First Department of Paediatrics, National and Kapodistrian University of Athens, Athens, Greece iopapadatou@med.uoa.gr.
authors.forename: Ioanna
authors.initials: I
authors.lastname: Papadatou
authors.affiliation: First Department of Paediatrics, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Vana
authors.initials: V
authors.lastname: Spoulou
mesh_terms: D000328:Adult; D000368:Aged; D002648:Child; D006801:Humans; D007108:Immune Tolerance; D007115:Immunization Schedule; D007117:Immunization, Secondary; D016867:Immunocompromised Host; D000071497:Immunogenicity, Vaccine; D011008:Pneumococcal Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000592:standards; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control; D012307:Risk Factors; D014611:Vaccination
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines